Madhan Kumar Soutallu Janakiram
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Madhan Kumar Soutallu Janakiram has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Ashok Kumar Janakiraman
Faculty of Pharmaceutical Sciences, UCSI University, 56000 Cheras, Kuala Lumpur, Malaysia
2 shared publications - Hanish Singh Jayasingh Chellammal
Department of Pharmacology and Life Sciences, Faculty of Pharmacy, Universiti Teknologi MARA (UiTM), Puncak Alam, Selangor, 42300, Malaysia; Group for Affinity, Safety and Efficacy Studies, Universiti Teknologi MARA (UiTM), Puncak Alam, Selangor, 42300, Malaysia; Brain Degeneration & Therapeutics Research Group, Universiti Teknologi MARA (UiTM), Puncak Alam, Selangor, 42300, Malaysia
2 shared publications - Alfonzo E. Muñoz Cabello
University of Houston, USA
1 shared publication - Chakravarthy Marx Sadacharan
Department of Biomedical Sciences, Anatomy & Embryology, Tilman J. Fertitta Family College of Medicine (TJFFCOM), University of Houston, Houston, USA
1 shared publication Cheng Wan Hee
Faculty of Health and Life Sciences, INTI International University-71800 Nilai, Malaysia
1 shared publicationDhani Ramachandran
Unit of Pathology, International Medical School, Management and Science University, Section 13, Shah Alam-40100, Selangor, Malaysia
1 shared publication
Latest Publications
- 22 May 2026
- Published by Bentham Science Publishers Ltd. in Current Alzheimer Research
- Vol. 23, 1-18
Immunotherapeutic Advances in Alzheimer’s Disease: The Convergence of Vaccinology and Nanoscience
Amyloid-beta plaques and neurofibrillary tangles promote neuronal dysfunction and cognitive loss, the hallmarks of Alzheimer's disease (AD), a serious global health concern. Current medications offer only symptomatic alleviation, emphasizing the critical need for disease-- modifying therapy. This study was performed using MeSH term search by using keywords, like “Alzheimer’s Disease”, “AD”, “Vaccines”, “Nanoformulations”, “Amyloid-Beta (Aβ) Vaccines”, “lecanemab”, “Tau protein Vaccines”, “AADvac1”, “Clinical trials”. The development of vaccines and methods based on nanotechnology is the primary focal point of this review, which explores immunotherapeutic approaches. Active and passive immunization are used in the development of AD vaccines to target tau and amyloid-beta pathology. While passive immunization involves the direct delivery of pre-formed antibodies, active immunization aims to stimulate the patient's own immune system to produce antibodies in response to the antigen. The necessity for effective drug delivery across the blood-brain barrier (BBB), safety issues, and inconsistent efficacy are some of the difficulties facing vaccine delivery strategies. Nanotechnology can overcome the drawbacks of traditional treatments by providing novel approaches for gene therapy, RNA-based interventions, and targeted medication administration. Immunization approaches offer multiple benefits, including regulated and targeted antigen release, as well as stabilizing the vaccine antigens. Therapeutic drugs can be delivered across the BBB, and genes linked to AD can be modulated by nanoparticles and liposomes that resemble exosomes. Current developments, including the incorporation of short Aβ epitopes, liposomal formulations, conformational mimotopes, and virus-- like particles (VLPs), have markedly enhanced vaccine tolerability. Effective AD treatments depend on combination medications, individualized approaches, and ongoing research into crossing the BBB and improving the safety and effectiveness of vaccines.
- 22 May 2026
- Published by Bentham Science Publishers Ltd. in Current Alzheimer Research
- Vol. 23, 1-18
Immunotherapeutic Advances in Alzheimer’s Disease: The Convergence of Vaccinology and Nanoscience
Amyloid-beta plaques and neurofibrillary tangles promote neuronal dysfunction and cognitive loss, the hallmarks of Alzheimer's disease (AD), a serious global health concern. Current medications offer only symptomatic alleviation, emphasizing the critical need for disease-- modifying therapy. This study was performed using MeSH term search by using keywords, like “Alzheimer’s Disease”, “AD”, “Vaccines”, “Nanoformulations”, “Amyloid-Beta (Aβ) Vaccines”, “lecanemab”, “Tau protein Vaccines”, “AADvac1”, “Clinical trials”. The development of vaccines and methods based on nanotechnology is the primary focal point of this review, which explores immunotherapeutic approaches. Active and passive immunization are used in the development of AD vaccines to target tau and amyloid-beta pathology. While passive immunization involves the direct delivery of pre-formed antibodies, active immunization aims to stimulate the patient's own immune system to produce antibodies in response to the antigen. The necessity for effective drug delivery across the blood-brain barrier (BBB), safety issues, and inconsistent efficacy are some of the difficulties facing vaccine delivery strategies. Nanotechnology can overcome the drawbacks of traditional treatments by providing novel approaches for gene therapy, RNA-based interventions, and targeted medication administration. Immunization approaches offer multiple benefits, including regulated and targeted antigen release, as well as stabilizing the vaccine antigens. Therapeutic drugs can be delivered across the BBB, and genes linked to AD can be modulated by nanoparticles and liposomes that resemble exosomes. Current developments, including the incorporation of short Aβ epitopes, liposomal formulations, conformational mimotopes, and virus-- like particles (VLPs), have markedly enhanced vaccine tolerability. Effective AD treatments depend on combination medications, individualized approaches, and ongoing research into crossing the BBB and improving the safety and effectiveness of vaccines.
- Open Access
- 27 February 2026
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
ADVANCES IN POLYPHENOL-BASED OCULAR DRUG DELIVERY: MECHANISTIC INSIGHTS, FORMULATION INNOVATIONS, AND TRANSLATIONAL PERSPECTIVES
Polyphenols, a structurally diverse class of plant-derived phytoconstituents, possess potent antioxidant, anti-inflammatory, and vasoprotective properties that make them promising therapeutic candidates for ocular disorders driven by oxidative stress, chronic inflammation, and overall health. Despite this potential, their clinical translation remains restricted due to the inherent limitations of conventional ocular delivery systems, such as low ocular bioavailability, rapid precorneal elimination, poor corneal permeability, and inadequate targeting of posterior ocular tissues. To address these challenges, recent research has focused on advanced formulation approaches designed to enhance polyphenol retention, penetration, and sustained release within ocular tissues. These include nanoemulsions, polymeric micelles lipid and polymer-based nanocarriers, in situ gelling systems, mucoadhesive and stimuli-responsive platforms, and advanced drug delivery platforms for the posterior and anterior ocular segments. Mechanistically, these systems exploit physicochemical and biological strategies such as enhancing mucoadhesion, modulating paracellular transport, and leveraging endocytic uptake to improve drug disposition and therapeutic performance. The review critically examines these innovative formulation platforms, delineates their pharmacokinetic and pharmacodynamic outcomes, and discusses safety, manufacturing challenges, and regulatory considerations that presently influence their clinical progression. Overall, it highlights emerging formulation technologies most likely to facilitate the successful clinical translation of polyphenol-based ocular therapies.
- 27 February 2026
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
Open AccessADVANCES IN POLYPHENOL-BASED OCULAR DRUG DELIVERY: MECHANISTIC INSIGHTS, FORMULATION INNOVATIONS, AND TRANSLATIONAL PERSPECTIVES
Polyphenols, a structurally diverse class of plant-derived phytoconstituents, possess potent antioxidant, anti-inflammatory, and vasoprotective properties that make them promising therapeutic candidates for ocular disorders driven by oxidative stress, chronic inflammation, and overall health. Despite this potential, their clinical translation remains restricted due to the inherent limitations of conventional ocular delivery systems, such as low ocular bioavailability, rapid precorneal elimination, poor corneal permeability, and inadequate targeting of posterior ocular tissues. To address these challenges, recent research has focused on advanced formulation approaches designed to enhance polyphenol retention, penetration, and sustained release within ocular tissues. These include nanoemulsions, polymeric micelles lipid and polymer-based nanocarriers, in situ gelling systems, mucoadhesive and stimuli-responsive platforms, and advanced drug delivery platforms for the posterior and anterior ocular segments. Mechanistically, these systems exploit physicochemical and biological strategies such as enhancing mucoadhesion, modulating paracellular transport, and leveraging endocytic uptake to improve drug disposition and therapeutic performance. The review critically examines these innovative formulation platforms, delineates their pharmacokinetic and pharmacodynamic outcomes, and discusses safety, manufacturing challenges, and regulatory considerations that presently influence their clinical progression. Overall, it highlights emerging formulation technologies most likely to facilitate the successful clinical translation of polyphenol-based ocular therapies.
- Open Access
- 28 January 2026
- Published by MDPI AG in Preprints.org
An Axillary Arch Muscle Variant with Potential Neurovascular Implications
The axillary arch (AA), also known as Langer’s axillary arch, is the most common muscular variation encountered in the axilla. It typically arises from the latissimus dorsi and traverses the axillary fossa, often crossing anterior to the neurovascular structures before inserting into the pectoralis major or surrounding fascia. Although frequently asymptomatic, this variant may cause neurovascular compression or complicate surgical procedures involving the axilla. During routine cadaveric dissection, an axillary arch muscle was identified in a 97-year-old male donor. The muscular slip originated from the medial border of the latissimus dorsi and inserted into the trilaminar tendon of the pectoralis major, passing anterior to the axillary artery and median nerve. No additional muscular variations were observed. This report highlights the anatomical features and clinical relevance of the axillary arch and emphasizes the importance of recognizing this variation to avoid diagnostic confusion and surgical complications.
- 28 January 2026
- Published by MDPI AG in Preprints.org
Open AccessAn Axillary Arch Muscle Variant with Potential Neurovascular Implications
The axillary arch (AA), also known as Langer’s axillary arch, is the most common muscular variation encountered in the axilla. It typically arises from the latissimus dorsi and traverses the axillary fossa, often crossing anterior to the neurovascular structures before inserting into the pectoralis major or surrounding fascia. Although frequently asymptomatic, this variant may cause neurovascular compression or complicate surgical procedures involving the axilla. During routine cadaveric dissection, an axillary arch muscle was identified in a 97-year-old male donor. The muscular slip originated from the medial border of the latissimus dorsi and inserted into the trilaminar tendon of the pectoralis major, passing anterior to the axillary artery and median nerve. No additional muscular variations were observed. This report highlights the anatomical features and clinical relevance of the axillary arch and emphasizes the importance of recognizing this variation to avoid diagnostic confusion and surgical complications.
- Open Access
- 5 September 2024
- Published by I MED Research Publications in International Journal of Anatomy and Research
- Vol. 12 (3) , 8996-9002
Histological and Immunohistochemical Study of the Beta Cells In Streptozotocin Induced Diabetic Rats Treated with Cynodon Dactylon Aqueous Extract
Background: Diabetes mellitus is a chronic metabolic disorder that affects human body in terms of physical, psychological and social health. Traditional medicines have been widely used in treatment of diabetes and its complications. After administrating the aqueous extract of Cynodon dactylon in streptozotocin induced diabetic rats, we evaluated the histological and immunohistochemical effects of the β – cells in the pancreatic islets. Objectives: The objective of the present study is to investigate the antidiabetic effect of Cynodon dactylon aqueous extract in β – cells of islets, against streptozotocin induced diabetic rats. Materials and Methods: In this study adult male albino rats were used. Aqueous extract of Cynodon dactylon (500 mg/kg.bw/day) administered orally for 45 days. At the end of experimental period, animals were sacrificed, pancreas was isolated and processed for histological and immunohistochemical analysis. Results: The pancreas of Cynodon dactylon aqueous extract treated diabetic rats showed improved islet morphology; and the pancreatic islets of the Cynodon dactylon aqueous extract treated diabetic rats showed consistent elevation in the insulin levels from the β – cells. Therefore, the antidiabetic activity of Cynodon dactylon aqueous extract might be due to the compounds present in the Cynodon dactylon aqueous extract which stimulate the insulin secretion and protect the intact functional β – cells from streptozotocin induced destruction. Conclusion: Cynodon dactylon aqueous extract increased the insulin secreting β – cells in the pancreatic islets and protecting the intact β – cells from oxidative damage. KEYWORDS: Cynodon dactylon, streptozotocin, Pancreatic islets, oxidative stress.
- 5 September 2024
- Published by I MED Research Publications in International Journal of Anatomy and Research
- Vol. 12 (3) , 8996-9002
Open AccessHistological and Immunohistochemical Study of the Beta Cells In Streptozotocin Induced Diabetic Rats Treated with Cynodon Dactylon Aqueous Extract
Background: Diabetes mellitus is a chronic metabolic disorder that affects human body in terms of physical, psychological and social health. Traditional medicines have been widely used in treatment of diabetes and its complications. After administrating the aqueous extract of Cynodon dactylon in streptozotocin induced diabetic rats, we evaluated the histological and immunohistochemical effects of the β – cells in the pancreatic islets. Objectives: The objective of the present study is to investigate the antidiabetic effect of Cynodon dactylon aqueous extract in β – cells of islets, against streptozotocin induced diabetic rats. Materials and Methods: In this study adult male albino rats were used. Aqueous extract of Cynodon dactylon (500 mg/kg.bw/day) administered orally for 45 days. At the end of experimental period, animals were sacrificed, pancreas was isolated and processed for histological and immunohistochemical analysis. Results: The pancreas of Cynodon dactylon aqueous extract treated diabetic rats showed improved islet morphology; and the pancreatic islets of the Cynodon dactylon aqueous extract treated diabetic rats showed consistent elevation in the insulin levels from the β – cells. Therefore, the antidiabetic activity of Cynodon dactylon aqueous extract might be due to the compounds present in the Cynodon dactylon aqueous extract which stimulate the insulin secretion and protect the intact functional β – cells from streptozotocin induced destruction. Conclusion: Cynodon dactylon aqueous extract increased the insulin secreting β – cells in the pancreatic islets and protecting the intact β – cells from oxidative damage. KEYWORDS: Cynodon dactylon, streptozotocin, Pancreatic islets, oxidative stress.